Beta Bionics, Inc. (NASDAQ:BBNX) Receives $23.20 Average Price Target from Analysts

Beta Bionics, Inc. (NASDAQ:BBNX) has received a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $23.20.

A number of research analysts recently issued reports on the stock. Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Robert W. Baird dropped their price target on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Stifel Nicolaus cut their price objective on Beta Bionics from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. The Goldman Sachs Group reiterated a “buy” rating and issued a $25.00 price objective on shares of Beta Bionics in a research report on Thursday, January 15th. Finally, Bank of America cut Beta Bionics from a “buy” rating to a “neutral” rating in a research note on Friday, January 9th.

Beta Bionics Stock Performance

NASDAQ:BBNX opened at $9.93 on Tuesday. The company has a market cap of $440.69 million, a price-to-earnings ratio of -5.09 and a beta of 5.06. Beta Bionics has a 52-week low of $8.89 and a 52-week high of $32.71. The stock’s fifty day moving average price is $12.33 and its two-hundred day moving average price is $20.87.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, February 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.12. The firm had revenue of $32.12 million for the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Insider Buying and Selling at Beta Bionics

In other Beta Bionics news, insider Mike Mensinger sold 2,200 shares of Beta Bionics stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total value of $66,220.00. Following the sale, the insider directly owned 80,752 shares in the company, valued at approximately $2,430,635.20. The trade was a 2.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 6,905 shares of company stock worth $124,095 over the last ninety days.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in Beta Bionics by 213.5% during the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after acquiring an additional 1,509,217 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Beta Bionics in the 4th quarter valued at about $40,437,000. Divisadero Street Capital Management LP acquired a new position in shares of Beta Bionics during the 2nd quarter worth about $13,817,000. Eversept Partners LP acquired a new position in shares of Beta Bionics during the 4th quarter worth about $20,667,000. Finally, 12 West Capital Management LP bought a new stake in shares of Beta Bionics in the 4th quarter valued at about $17,520,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.